Febustad 40 Stella medicine for hyperuric hyperuricemia (3 blisters x 10 tablets)

Dosage form Box of 3 blisters x 10 tablets
Specifications Febuxostat

Ingredient

Composition information	Content
Febuxostat	40mg

Uses

Indications

Febustad 40 drugs are indicated in the following cases: The treatment of chronic hyperuricemia in patients with gout. Febuxostat is not recommended for the treatment of asymptomatic uric acid.

Pharmacokology

Pharmacological group: Treatment of gout, inhibiting uric acid production.

Febuxostat inhibits xathin oxidase, is the enzyme that catalyzes hypoxanthin into xanthin and xanthin into uric acid.

By preventing uric acid production, Febuxostat reduces the serum concentration of uric acid. Febuxostat has very little impact on other enzymes participating in synthesizing and transforming purin and pyrimidin.

pharmacokinetic

absorption

Febuxostat is absorbed quickly and well after drinking. Although the drug is used with a fat -rich meal that reduces the peak concentration and the level of contact in plasma, this is not clinically significant. Febuxostat can be taken with or not at the same meal.

Distribution

The level of cohesion with plasma protein is about 99%.

Metabolism

Febuxostat is widely metabolized thanks to the conjugate with the uridin diphosphate glucuronosyltransferase (UDPGT) and Oxygen through isenzyme cytochrome P450, the main metabolites are actively formed by: UGT1A1, UGT1A8, UGT19 AVFEBOXOXOXOXOXOSTATY CYP2C8 or CYP2C9.

Elimination

Febuxostat has the last waste time of about 5-8 hours, about half the dose is eliminated through the urine, the rest is excreted through feces.

Before taking Febustad 40 Stella medicine for hyperuric hyperuricemia (3 blisters x 10 tablets)

How to use

Take oral use and regardless of meals and antacids.

Dosage

recommend the starting dose of Febuxostat in controlling blood uric acid in patients with gout is 40mg x 1 time/day.

The dose of Febuxostat can increase to 80mg x 1 time/day in patients who do not achieve serum urate levels below 6mg/dl after 2 weeks of treatment with Febuxostat at a dose of 40mg x 1 time/day.

No dose adjustment for patients with mild to medium or liver impairment.

Children

Efficiency and safety of Febuxostat has not been established with children under 18 years old.

Elderly

No dose adjustment.

Note: The above dose is for reference only. Specific dosage depends on the condition and level of progression of the disease. For a suitable dose, you need to consult a doctor or medical specialist.

What to do when overdose? Patients need symptomatic treatment and support care when overdose.

What to do when forgetting a dose? However, if close to the next dose, skip the forgotten dose and take the next dose at the time as planned. Do not use double the prescribed dose.

Side Effects

When using Febustad 40, you may experience unwanted effects (ADR).

Common, ADR> 1/100

Metabolism and nutrition: Gout recurrence.

Neurology: headache.

Digestive: diarrhea, nausea.

liver - bile: abnormal liver function.

Skin and subcutaneous tissue: rash.

Overall: edema.

Uncommon, 1/1000

Endocrine: Increasing thyroid stimulating hormones.

Metabolism and nutrition: Diabetes, hyperlipidemia, reducing appetite and weight gain.

Mental: Reduce sex, insomnia.

Neurological: dizziness, paresthesia, paralysis, drowsiness, change taste, reduce tactile, reduce smell.

Heart: Atrial fibrillation, chest drum, abnormal ECG.

circuit: Hypertension, flushing, hot.

Digestive: abdominal pain, bloating, gastroesophageal reflux syndrome, vomiting, dry mouth, indigestion, constipation, often diarrhea, flatulence, discomfort with digestive tract.

liver - bile: gallstones.

Skin and subcutaneous tissue: dermatitis, urticaria, itching, skin discoloration, skin damage, hemorrhagic spots, tracing rashes, notes.

musculoskeletal and connective tissue: joint pain, joints, muscle pain, musculoskeletal, muscle weakness, muscle spasms, muscle inflammation, epidemic inflammation.

Kidney and urinary: kidney failure, ureter, bleeding, urination, proteinuria.

Reproduction and mammary gland: erectile dysfunction.

Overall: fatigue, chest pain, uncomfortable chest.

Less, 1/10000

Blood and lymphatic system: Reducing all bloody, platelets.

Immune: Anaphylaxis, sensitivity to the drug.

Eyes: blurred vision.

Metabolism and nutrition: Losing weight, increasing appetite or anorexia.

Mental: Stress

ears and inner ears: tinnitus.

digestive: pancreatitis, mouth ulcer.

liver - bile: hepatitis, jaundice, liver damage.

Skin and subcutaneous tissue: Poisoned epidermal necrosis, Steven - Johnson syndrome, angioedema, drug reaction with eosinophilia and overall symptoms, body rash, rose rash, flaking rash, cystic rash, blister rash, Red rash, Red rash, measles rash, hair loss, sweat increase.

musculoskeletal and connective tissue: muscle pattern, stiffness, muscle - bone.

Kidney and urinary tract: Interstitial nephritis - Kidney, urination.

Overall: Thirst.

Instructions on how to handle ADR

When experiencing side effects of the drug, it is necessary to stop using and notify the doctor or go to the nearest medical facility for timely treatment.

Warnings

Before using the drug you need to read the instructions carefully and refer to the information below.

Contraindicated

Febuxostat 40 contraindications in the following cases:

Hypersensitivity to any ingredients of the drug.

Used with azathioprin, mercaptopurin, theophyllin.

Caution when using

Gout recurrence: Gout increases when starting to use anti -uric acid tank agents, including febuxostat. If the Gout attack occurs in treatment, no need to stop Febuxostat. Preventive treatment (for example, nonsteroidal anti -inflammatory drugs (NSAID) or Colchicin at the beginning of treatment) can reduce gout to 6 months.

Affects on cardiovascular disease: The rate of reporting cardiac embarrowerment events has been found in patients treated with higher febuxostat than allopurinol in clinical trials. Monitor the signs and symptoms of myocardial infarction and stroke.

Effects on the liver: There is a report on liver failure, sometimes death. Do not exclude the cause of the use of the drug. If the liver damage is detected, stop using Febuxostat and evaluate the cause may occur in the patient, then treat it if possible, to be able to decide to stop the drug or maintain. Do not reuse Febuxostat if the liver damage is confirmed and does not find another cause.

allergies/sensitivity to drugs: Patients should be known and closely monitor the signs and symptoms of allergic/sensitive reactions. Discontinue treatment with Febuxostat immediately if there is an allergic/sensitive reaction like Steven - Johnson syndrome. If allergic/sensitivity reactions increase like allergic/sensitive reactions and acute anaphylaxis/anaphylactic reactions. Do not reuse Febuxostat for patients any more.

Febuxostat 40 contains lactose excipients. This drug should not be used for patients with rare genetic problems galacotse intolerance, total lactase enzyme deficiency or poorly absorbing Glucose - Galactose.

The ability to drive and operate machinery

Sleep, dizzy, abnormal and blurred vision has been reported with the use of Febuxostat. Patients should be careful to use before driving, using machinery or participating in dangerous activities for HI, they are sure that Febuxostat does not adversely affect the implementation of these activities.

Pregnancy

There is no complete and well -controlled study in pregnant women. Febuxostat should only be used during pregnancy when considering the benefits and potential risks for the fetus.

Breastfeeding period

Febuxostat is excreted in mother mouse milk. It is unknown whether the drug is excreted in breast milk or not, so be careful when using Febuxostat in nursing women.

Drug interaction

Due to the inhibition of xanthin oxydase, it is an increase in Mercaptopurin or azathoprin level, so it should not be used Febuxostat with the above drugs. Similarly, when using simultaneously Febuxostat with theophyllin, theoophyllin concentration should be monitored.

Febuxostat is metabolized through the uridin diphosphate glucuronosyltransferase system, which can affect the effect of Febuxostat. Track serum uric acid after 1-2 weeks after treatment with strong induction with glucorididation.

Storage

In closed packaging, dry place. The temperature does not exceed 300C.

Other drugs

Disclaimer

Every effort has been made to ensure that the information provided by Drugslib.com is accurate, up-to-date, and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. Drugslib.com information has been compiled for use by healthcare practitioners and consumers in the United States and therefore Drugslib.com does not warrant that uses outside of the United States are appropriate, unless specifically indicated otherwise. Drugslib.com's drug information does not endorse drugs, diagnose patients or recommend therapy. Drugslib.com's drug information is an informational resource designed to assist licensed healthcare practitioners in caring for their patients and/or to serve consumers viewing this service as a supplement to, and not a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners.

The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective or appropriate for any given patient. Drugslib.com does not assume any responsibility for any aspect of healthcare administered with the aid of information Drugslib.com provides. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.